Medication Intelligence Leader Kit CheckⓇ Rebrands as BluesightⓇ The shift redefines Bluesight from a point solution to a suite of Medication Intelligence™ software products that provides a complete picture of the pharmaceutical supply chain Alexandria, VA (December...
PASSAGE BIO ANNOUNCES POSITIVE INTERIM CLINICAL DATA FROM FIRST SIX PATIENTS WITH GM1 GANGLIOSIDOSIS IN IMAGINE-1 STUDY Interim safety data up to 20 months showed the low and high dose of PBGM01 were well tolerated and had a favorable safety profile Intra-cisterna...
Arvinas Announces ARV-471 Achieves a Clinical Benefit Rate of 38% in Evaluable Patients and Continues to Show a Favorable Tolerability Profile in its Phase 2 Expansion Trial (VERITAC) ARV-471 continues to show activity in heavily pre-treated patients with locally...
AbCellera and Rallybio Announce Strategic Alliance to Discover, Develop, and Commercialize Novel Antibody-Based Therapeutics for Rare Diseases VANCOUVER, British Columbia & NEW HAVEN, Conn.–(BUSINESS WIRE)–Dec. 1, 2022– AbCellera (Nasdaq: ABCL)...
Rallybio Announces Publication of Data Highlighting the Ability of HPA-1a-Specific Antibodies to Prevent Alloimmunization in an Authentic Mouse Model of FNAIT — Data Demonstrates that HPA-1a Alloimmunization can be Prevented with Prophylactic Administration of...
Iterum Therapeutics announces Issuance of Allowance for a U.S. Patent Covering Oral Sulopenem DUBLIN, Ireland and CHICAGO, Dec. 15, 2022 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum”), a clinical-stage pharmaceutical...
Recent Comments